Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Presses Generics Firms to Speed Adoption of QbD, While Questions on Use of Prior Knowledge Persist

This article was originally published in The Gold Sheet

Executive Summary

FDA officials are telling generic drug makers that the agency will be looking for their abbreviated new drug applications to include the type of pharmaceutical development studies and risk assessments that are spelled out in recent guidelines from the International Conference on Harmonization.

You may also be interested in...



FDA Warns Generics Firms About January QbD Deadline for ANDAs

Come January, if there is no quality target product profile (QTPP) in an abbreviated new drug application (ANDA), FDA might not file it, agency officials told a Generic Pharmaceutical Association workshop. Even though quality by design (QbD) remains optional for brand drugs, it will be expected for generics, said Office of Generic Drugs representatives who went on to outline pending question-based-review (QbR) revisions designed to elicit QbD information.

In Brief

FDA mulls third-party inspections

FDA Mulls Requiring QbD as Some Generics Firms and Others Resist It

Quality by Design could become mandatory in the U.S. as FDA seeks ways to motivate the last holdouts from the new drug quality paradigm. Some generics firms want FDA to make them do it so competitors won't take first-to-file short cuts. FDA also looks to develop guidance that provides greater detail on how to use QbD. The agency also is working to help old-school reviewers with empirical mindsets to embrace new science-based QbD approaches.

Related Content

UsernamePublicRestriction

Register

PS000596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel